CN115400044A - 一种纳米双抗精华肌底液及其制备方法 - Google Patents
一种纳米双抗精华肌底液及其制备方法 Download PDFInfo
- Publication number
- CN115400044A CN115400044A CN202211143484.6A CN202211143484A CN115400044A CN 115400044 A CN115400044 A CN 115400044A CN 202211143484 A CN202211143484 A CN 202211143484A CN 115400044 A CN115400044 A CN 115400044A
- Authority
- CN
- China
- Prior art keywords
- parts
- component
- stirring
- essence
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title abstract description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 60
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000002994 raw material Substances 0.000 claims abstract description 24
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 20
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims abstract description 20
- 229960003237 betaine Drugs 0.000 claims abstract description 20
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 20
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 20
- 210000003205 muscle Anatomy 0.000 claims abstract description 15
- 238000006206 glycosylation reaction Methods 0.000 claims abstract description 11
- 239000012530 fluid Substances 0.000 claims abstract description 10
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 6
- 239000006210 lotion Substances 0.000 claims abstract description 5
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 4
- 230000003064 anti-oxidating effect Effects 0.000 claims abstract description 3
- 238000003756 stirring Methods 0.000 claims description 53
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 21
- 108010087806 Carnosine Proteins 0.000 claims description 21
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 21
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical group [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 21
- 229940044199 carnosine Drugs 0.000 claims description 21
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 19
- 235000013793 astaxanthin Nutrition 0.000 claims description 19
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 19
- 229940022405 astaxanthin Drugs 0.000 claims description 19
- 239000001168 astaxanthin Substances 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 12
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000008213 purified water Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 9
- 230000000249 desinfective effect Effects 0.000 claims description 9
- 229940035423 ethyl ether Drugs 0.000 claims description 9
- 229960005150 glycerol Drugs 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000009977 dual effect Effects 0.000 claims 3
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 6
- 229960005323 phenoxyethanol Drugs 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 102000003425 Tyrosinase Human genes 0.000 description 5
- 108060008724 Tyrosinase Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 230000032683 aging Effects 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000013543 active substance Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- -1 methyl propylene glycol compound Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 1
- ZGSCRDSBTNQPMS-UJURSFKZSA-N 3-O-Ethylascorbic acid Chemical group CCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO ZGSCRDSBTNQPMS-UJURSFKZSA-N 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229940100573 methylpropanediol Drugs 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000005995 skin dysfunction Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于医疗美容技术领域,尤其涉及一种纳米双抗精华肌底液及其制备方法。本发明所述肌底液包括A组分和B组分;所述A组分包括以下原料:抗糖基化成分、百花玉屏油、吐温80;所述B组分包括以下原料:vc乙基醚、甘油、甜菜碱、抗氧化成分、辛酰羟肟酸复合物、水。本发明所述的纳米双抗精华肌底液,是水包油的纳米体系,抗糖基化,抗氧化,易吸收,使用过程中温和舒适。
Description
技术领域
本发明属于医疗美容技术领域,尤其涉及一种纳米双抗精华肌底液及其制备方法。
背景技术
现在普遍认为衰老的原因有三种,分别是:自由基、光老化和糖化。
人体含有许多自由基,主要是因为人体的正常的生理活动或者外界的日晒等原因形成。适量的自由基会对细胞的生理活动等方面有着积极的作用,但超过一定数量则会与体内的不饱和脂肪酸反应,从而生成过氧化物,引起蛋白质变质甚至失活等,甚至造成细胞的解体或者死亡。同时造成衰老的主要原因就是氧化,并且人体组织也会受过多的氧自由基影响,造成损害,从而使得原本的新陈代谢功能受影响,引起皮肤的色素沉着、长斑甚至会引起某些疾病。
非酶糖基化是由蛋白质或游离氨基酸中的氨基基团在还原糖及活性羰基的作用下通过非酶促糖化作用形成分子内或分子间交联,最终不可逆转地产生非酶糖基化终末产物。非酶糖基化终末产物随年龄的增长在各种组织中积累,主要累及周转速度慢、富含赖氨酸的蛋白质。进一步加重了皮肤功能障碍,导致皮肤弹性下降、皱纹产生、含水量减少。
肌肽可以显著减少氧化产物及糖化产物如活性氧类、丙二醛及非酶糖基化终末产物等的积累,从而减轻组织器官的损伤。其可能机制是,在三价铁离子存在条件下,减弱非酶糖基化终末产物导致DNA裂解。肌肽可以通过保护线粒体功能及减少活性氧的产生延缓衰老。维生素C乙基醚是一种非常有用的维生素C衍生物,也具有很强的抗氧化作用。
化妆品配方中添加抗衰的活性成分,可以有效抑制衰老。然而,活性成分在化妆品中的应用存在二大瓶颈:一是这些活性成分大多自身不稳定,且易受外界环境影响或配方原料配伍性不佳而失活;二是在使用过程中,很多活性物质并不能有效渗透到皮肤角质层发挥实际功效。
因而,使用纳米技术对活性成分进行包覆,从而在保护功效成分稳定性的同时提高其对皮肤的渗透性,促进在皮肤表层的有效吸收,成为抗衰老化妆品配制的新思路和新选择。
发明内容
为解决上述现有技术中存在的问题,本发明提供了一种纳米双抗精华肌底液及其制备方法,该肌底液安全无刺激,吸收好,抗糖基化抗氧化效果好。
为实现上述目的,本发明采用如下技术方案:
一种纳米双抗精华肌底液,包括A组分和B组分;
所述A组分包括以下重量份的原料:抗糖基化成分0.01-2份、百花玉屏油0.1-2份、吐温80 0.1-3份;
所述B组分包括以下重量份的原料:vc乙基醚0.1-3份、甘油1-5份、甜菜碱1-5份、抗氧化成分0.1-2份、辛酰羟肟酸复合物1-5份、水80-99份。
优选的,所述抗糖基化成分为虾青素。
优选的,所述抗氧化成分为肌肽。
本发明还公开了上述的纳米双抗精华肌底液的制备方法,包括以下步骤:
1)配制A相:将虾青素、百花玉屏油和吐温80混合均匀,搅拌15min,备用;
2)将纯化水加热消毒冷却后备用;
3)配制B相:将vc乙基醚、甘油、甜菜碱、肌肽、辛酰羟肟酸复合物和水搅拌均匀;
4)将A相放入磁力搅拌器中继续搅拌,用滴管将B相缓慢滴入A相中,此过程边滴加边搅拌,滴加速度为20s/滴;
5)凝胶相结束以后,暂停滴加,在磁力搅拌器中搅拌10min;
6)滴加速度改为1s/滴,直至全部加完,至料体充分搅拌均匀,即得到所述肌底液。
有益效果
本发明公开了一种纳米双抗精华肌底液及其制备方法,本发明所述的纳米双抗精华肌底液,是水包油的纳米体系。本发明提供的纳米乳可有效提高活性物质的溶解度,增强活性成分的渗透性,提高皮肤滞留量。
本发明所述的纳米双抗精华肌底液包含抗糖化成分和抗氧化成分,利用纳米技术对活性成分进行包覆,提高了其对皮肤的渗透性,从而达到高效抗衰的效果。
具体实施方式
以下,将详细地描述本发明。在进行描述之前,应当理解的是,在本说明书和所附的权利要求书中使用的术语不应解释为限制于一般含义和字典含义,而应当在允许发明人适当定义术语以进行最佳解释的原则的基础上,根据与本发明的技术方面相应的含义和概念进行解释。因此,这里提出的描述仅仅是出于举例说明目的的优选实例,并非意图限制本发明的范围,从而应当理解的是,在不偏离本发明的精神和范围的情况下,可以由其获得其他等价方式或改进方式。
以下实施例仅是作为本发明的实施方案的例子列举,并不对本发明构成任何限制,本领域技术人员可以理解在不偏离本发明的实质和构思的范围内的修改均落入本发明的保护范围。除非特别说明,以下实施例中使用的试剂和仪器均为市售可得产品。
实施例1
一种纳米双抗精华肌底液,包括A组分和B组分;
所述A组分包括以下重量份的原料:虾青素0.01-2份、百花玉屏油0.1-2份、吐温800.1-3份;
所述B组分包括以下重量份的原料:vc乙基醚0.1-3份、甘油1-5份、甜菜碱1-5份、肌肽0.1-2份、辛酰羟肟酸复合物1-5份、水80-99份。
所述纳米双抗精华肌底液的制备方法,包括以下步骤:
1)虾青素、百花玉屏油和吐温80混合均匀,搅拌15min,备用;
2)将纯化水加热消毒冷却后备用;
3)将vc乙基醚、甘油、甜菜碱、肌肽、辛酰羟肟酸复合物和水搅拌均匀;
4)将A相放入磁力搅拌器中继续搅拌,用滴管将B相缓慢滴入A相中,此过程边滴加边搅拌,滴加速度为20s/滴;
5)凝胶相结束以后,暂停滴加,在磁力搅拌器中搅拌10min;
6)滴加速度改为1s/滴,直至全部加完。至料体充分搅拌均匀,即得到所述肌底液。
实施例2
一种纳米双抗精华肌底液,包括A组分和B组分;所述A组分包括以下重量份的原料:虾青素0.01-2份、百花玉屏油0.1-2份、吐温80 0.1-3份;
所述B组分包括以下重量份的原料:vc乙基醚0.1-3份、甘油1-5份、甜菜碱1-5份、肌肽0.1-2份、辛酰羟肟酸复合物1-5份、水80-99份。
所述纳米双抗精华肌底液的制备方法,包括以下步骤:
1)虾青素、百花玉屏油和吐温80混合均匀,搅拌15min,备用;
2)将纯化水加热消毒冷却后备用;
3)将vc乙基醚、甘油、甜菜碱、肌肽、辛酰羟肟酸复合物和水搅拌均匀;
4)将A相放入磁力搅拌器中继续搅拌,用滴管将B相缓慢滴入A相中,此过程边滴加边搅拌,滴加速度为20s/滴;
5)凝胶相结束以后,暂停滴加,在磁力搅拌器中搅拌10min;
6)滴加速度改为1s/滴,直至全部加完。至料体充分搅拌均匀,即得到所述肌底液。
实施例3
一种纳米双抗精华肌底液,包括A组分和B组分;
所述A组分包括以下重量份的原料:虾青素0.01-2份、百花玉屏油0.1-2份、吐温800.1-3份;
所述B组分包括以下重量份的原料:vc乙基醚0.1-3份、甘油1-5份、甜菜碱1-5份、肌肽0.1-2份、辛酰羟肟酸复合物1-5份、水80-99份。
所述纳米双抗精华肌底液的制备方法,包括以下步骤:
1)虾青素、百花玉屏油和吐温80混合均匀,搅拌15min,备用;
2)将纯化水加热消毒冷却后备用;
3)将vc乙基醚、甘油、甜菜碱、肌肽、辛酰羟肟酸复合物和水搅拌均匀;
4)将A相放入磁力搅拌器中继续搅拌,用滴管将B相缓慢滴入A相中,此过程边滴加边搅拌,滴加速度为20s/滴;
5)凝胶相结束以后,暂停滴加,在磁力搅拌器中搅拌10min;
6)滴加速度改为1s/滴,直至全部加完。至料体充分搅拌均匀,即得到所述肌底液。
对比例1
一种纳米双抗精华肌底液,包括A组分和B组分;
所述A组分包括以下重量份的原料:虾青素0.01-2份、百花玉屏油0.1-2份、吐温800.1-3份;
所述B组分包括以下重量份的原料:vc乙基醚0.1-3份、甘油1-5份、甜菜碱1-5份、肌肽0.1-2份、苯氧乙醇1-5份、水80-99份。
所述纳米双抗精华肌底液的制备方法,包括以下步骤:
1)虾青素、百花玉屏油和吐温80混合均匀,搅拌15min,备用;
2)将纯化水加热消毒冷却后备用;
3)将vc乙基醚、甘油、甜菜碱、肌肽、苯氧乙醇和水搅拌均匀;
4)将A相放入磁力搅拌器中继续搅拌,用滴管将B相缓慢滴入A相中,此过程边滴加边搅拌,滴加速度为20s/滴;
5)凝胶相结束以后,暂停滴加,在磁力搅拌器中搅拌10min;
6)滴加速度改为1s/滴,直至全部加完。至料体充分搅拌均匀,即得到所述肌底液。
对比例2
一种纳米双抗精华肌底液,包括A组分和B组分;
所述A组分包括以下重量份的原料:虾青素0.01-2份、百花玉屏油0.1-2份、吐温800.1-3份;
所述B组分包括以下重量份的原料:vc乙基醚0.1-3份、甘油1-5份、甜菜碱1-5份、肌肽0.1-2份、甲基丙二醇复合物1-5份、水80-99份。
所述纳米双抗精华肌底液的制备方法,包括以下步骤:
1)虾青素、百花玉屏油和吐温80混合均匀,搅拌15min,备用;
2)将纯化水加热消毒冷却后备用;
3)将vc乙基醚、甘油、甜菜碱、肌肽、甲基丙二醇复合物和水搅拌均匀;
4)将A相放入磁力搅拌器中继续搅拌,用滴管将B相缓慢滴入A相中,此过程边滴加边搅拌,滴加速度为20s/滴;
5)凝胶相结束以后,暂停滴加,在磁力搅拌器中搅拌10min;
6)滴加速度改为1s/滴,直至全部加完。至料体充分搅拌均匀,即得到所述肌底液。
对比例3
一种纳米双抗精华肌底液,包括A组分和B组分;
所述A组分包括以下重量份的原料:虾青素0.001-1份、百花玉屏油0.1-2份、吐温80 0.1-3份;
所述B组分包括以下重量份的原料:vc乙基醚0.1-3份、甘油1-5份、甜菜碱1-5份、肌肽0.1-2份、苯氧乙醇1-5份、水80-99份。
所述纳米双抗精华肌底液的制备方法,包括以下步骤:
1)虾青素、百花玉屏油和吐温80混合均匀,搅拌15min,备用;
2)将纯化水加热消毒冷却后备用;
3)将vc乙基醚、甘油、甜菜碱、肌肽、苯氧乙醇和水搅拌均匀;
4)将A相放入磁力搅拌器中继续搅拌,用滴管将B相缓慢滴入A相中,此过程边滴加边搅拌,滴加速度为20s/滴;
5)凝胶相结束以后,暂停滴加,在磁力搅拌器中搅拌10min;
6)滴加速度改为1s/滴,直至全部加完。至料体充分搅拌均匀,即得到所述肌底液。
对比例4
一种纳米双抗精华肌底液,包括A组分和B组分;
所述A组分包括以下重量份的原料:百花玉屏油0.1-2份、吐温80 0.1-3份;
所述B组分包括以下重量份的原料:vc乙基醚0.1-3份、甘油1-5份、甜菜碱1-5份、肌肽0.1-2份、苯氧乙醇1-5份、水80-99份。
所述纳米双抗精华肌底液的制备方法,包括以下步骤:
1)虾青素、百花玉屏油和吐温80混合均匀,搅拌15min,备用;
2)将纯化水加热消毒冷却后备用;
3)将vc乙基醚、甘油、甜菜碱、肌肽、苯氧乙醇和水搅拌均匀;
4)将A相放入磁力搅拌器中继续搅拌,用滴管将B相缓慢滴入A相中,此过程边滴加边搅拌,滴加速度为20s/滴;
5)凝胶相结束以后,暂停滴加,在磁力搅拌器中搅拌10min;
6)滴加速度改为1s/滴,直至全部加完。至料体充分搅拌均匀,即得到所述肌底液。
实验例1抗氧化效果检测
自由基(DPPH)清除实验方法:
使用10mL试管设立样品管(T)、样品本底(T0)、DPPH管(C)和溶剂本底(C0),每一样品的每个受试浓度的样品管(T)需设立3支平行管,同时DPPH管(C)也需设立3支平行管。在样品管(T)和样品本底(T0)中各加入1mL相同浓度的样品溶液。在所有试管中(T、T0、C、C0)补充溶剂,水溶性样品用水,油溶性样品用95%乙醇,补足3mL,混匀。在样品管(T)和DPPH管(C)中加入DPPH乙醇溶液1mL,样品本底(T0)和溶剂本底(C0)用95%乙醇代替,轻轻摇匀,室温下静置5分钟。将各支反应溶液移入1cm比色皿中,在517nm处测定吸光值。实验结果如下表1所示。
表1自由基清除率
实验例2美白效果检测
酪氨酸酶活性抑制实验方法:
使用10mL试管设立样品管(T)、样品本底(T0)、酶反应管(C)和溶剂本底(C0),每一样品的每个受试浓度的样品管(T)需设立3支平行管,同时酶反应管(C)也需设立3支平行管。在样品管(T)和样品本底(T0)中各加入1mL相同浓度的样品溶液,酶反应管(C)和溶剂本底(C0)则分别加入1mL磷酸氢二钠-柠檬酸缓冲液。在样品管(T)和酶反应管(C)中各加入0.5mL酪氨酸酶溶液,样品本底(T0)与溶剂本底(C0)以0.5mL磷酸氢二钠-柠檬酸缓冲液代替,将样品和酪氨酸酶充分混匀,置37℃水浴槽孵育10分钟。依次在各管中加入2mL的左旋多巴溶液,控制每管反应时间为5分钟,即刻将各管反应溶液移入比色皿中,在475nm处测定吸光值。实验结果如下表2所示。
表2酪氨酸酶抑制率
以上的实验说明,虾青素的添加量对自由基清除率和酪氨酸酶抑制率的影响很大,配方中添加辛酰羟肟酸复合物和甲基丙二醇复合物的效果最好。
以上实施例仅用以说明本发明的技术方案,而非对其进行限制;尽管参照前述实施例对本发明进行了详细的说明,对于本领域的普通技术人员来说,依然可以对前述实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或替换,并不使相应技术方案的本质脱离本发明所要求保护的技术方案的精神和范围。
Claims (6)
1.一种纳米双抗精华肌底液,其特征在于,包括A组分和B组分;
所述A组分包括以下原料:抗糖基化成分、百花玉屏油、吐温80;
所述B组分包括以下原料:vc乙基醚、甘油、甜菜碱、抗氧化成分、辛酰羟肟酸复合物、水。
2.根据权利要求1所述的纳米双抗精华肌底液,其特征在于,所述抗糖基化成分为虾青素。
3.根据权利要求1所述的纳米双抗精华肌底液,其特征在于,所述抗氧化成分为肌肽。
4.根据权利要求2所述的纳米双抗精华肌底液,其特征在于,所述A组分包括以下重量份的原料:虾青素0.01-2份、百花玉屏油 0.1-2份、吐温80 0.1-3份。
5.根据权利要求3所述的纳米双抗精华肌底液,其特征在于,所述B组分包括以下重量份的原料:vc乙基醚 0.1-3份、甘油 1-5份、甜菜碱 1-5份、肌肽 0.1-2份、辛酰羟肟酸复合物1-5份、水 80-99份。
6.权利要求1-5任一所述的纳米双抗精华肌底液的制备方法,其特征在于,包括以下步骤:
(1)将虾青素、百花玉屏油和吐温80混合均匀,搅拌,得到A组分混合物,备用;
将纯化水加热消毒冷却后,得到处理后的纯化水备用;
(3)将vc乙基醚、甘油、甜菜碱、肌肽、辛酰羟肟酸复合物和步骤(2)所得处理后的纯化水搅拌均匀,得到凝胶相,备用;
(4)将步骤(1)所得A组分混合物放入磁力搅拌器中继续搅拌,用滴管将步骤(3)所得凝胶相缓慢滴入A组分混合物中,此过程边滴加边搅拌,滴加速度为20s/滴;
(5)凝胶相结束以后,暂停滴加,在磁力搅拌器中搅拌10min,得到两相混合物,备用;
(6)将B组分剩余的原料混合均匀,滴加速度改为1s/滴,滴入两相混合物中,直至全部加完,至料体充分搅拌均匀,即得到所述肌底液。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211143484.6A CN115400044A (zh) | 2022-09-20 | 2022-09-20 | 一种纳米双抗精华肌底液及其制备方法 |
CN202311208643.0A CN117100622A (zh) | 2022-09-20 | 2023-09-19 | 一种纳米双抗精华肌底液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211143484.6A CN115400044A (zh) | 2022-09-20 | 2022-09-20 | 一种纳米双抗精华肌底液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115400044A true CN115400044A (zh) | 2022-11-29 |
Family
ID=84166840
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211143484.6A Pending CN115400044A (zh) | 2022-09-20 | 2022-09-20 | 一种纳米双抗精华肌底液及其制备方法 |
CN202311208643.0A Pending CN117100622A (zh) | 2022-09-20 | 2023-09-19 | 一种纳米双抗精华肌底液及其制备方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311208643.0A Pending CN117100622A (zh) | 2022-09-20 | 2023-09-19 | 一种纳米双抗精华肌底液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN115400044A (zh) |
-
2022
- 2022-09-20 CN CN202211143484.6A patent/CN115400044A/zh active Pending
-
2023
- 2023-09-19 CN CN202311208643.0A patent/CN117100622A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN117100622A (zh) | 2023-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010132639A (ja) | Dna損傷抑制剤及びマトリックスメタロプロテアーゼ−1産生抑制剤 | |
RU2572505C2 (ru) | КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОР NFкВ И СТИМУЛЯТОР ОБРАЗОВАНИЯ ТРОПОЭЛАСТИНА | |
WO2022228268A1 (zh) | 虾青素组合物及其制备方法和应用 | |
CN113081890A (zh) | 一种具有抗糖抗氧化功能的精华液及其制作方法 | |
KR102301123B1 (ko) | 혼합 항산화제를 사용하여 안정화시킨 레티놀을 함유하는 화장료 조성물 | |
JP2005200370A (ja) | 一酸化窒素産生促進剤およびその利用 | |
JPS63284109A (ja) | 美白化粧料 | |
US5849309A (en) | Skin activator with glycosaminoglycan production-accelerating effect | |
KR20130031988A (ko) | 플로랄진세노사이드를 함유하는 피부 외용제 조성물 | |
JP5530058B2 (ja) | カロテノイドが安定化された水性製剤 | |
JP2005343882A (ja) | ヒアルロン酸産生促進剤、アクアポリン合成促進剤、及び皮膚外用剤組成物 | |
KR20180136301A (ko) | 물질 p를 포함하는 주름 개선 또는 항염증 화장료 조성물 | |
CN115400044A (zh) | 一种纳米双抗精华肌底液及其制备方法 | |
JP3117275B2 (ja) | フェルラ酸含有化粧料 | |
CN115607476A (zh) | 一种具有保湿抗氧化功效的组合物及其应用 | |
WO2012105632A1 (ja) | 皮膚外用剤 | |
JP5154780B2 (ja) | 一酸化窒素産生促進剤及びその利用 | |
JPH04187618A (ja) | 皮膚外用剤 | |
CN115700114A (zh) | 一种抗衰老组合物、其应用及包含该组合物的眼霜 | |
JP2006282536A (ja) | スーパーオキサイド消去剤、ラジカル消去剤、過酸化水素消去剤および皮膚外用剤 | |
KR101202006B1 (ko) | 비타민 u를 유효성분으로 함유하는 상처치유 및 피부 주름개선용 화장료 조성물 | |
JPWO2020111047A1 (ja) | 頭皮頭髪用組成物 | |
JP3382146B2 (ja) | 皮膚外用剤 | |
JPH04282320A (ja) | 化粧料 | |
CN115381732B (zh) | 一种羟丙基环糊精包合视黄醇的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20221129 |
|
WD01 | Invention patent application deemed withdrawn after publication |